A Prospective Study to Evaluate the Effect of Systemic Adjuvant Therapy on the Cognitive Function of Breast Cancer Patients
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The primary objective of this prospective pilot study is to examine the variation of cognitive function at various time-points in stage I-III breast cancer patients who have undergone or are undergoing adjuvant systemic therapy (chemotherapy and/or anti-hormonal therapy) and compare this to a group of healthy controls to evaluate if there is a difference. All randomized patients and their respective controls would be required to complete the computerized neuropsychological assessment CANTAB at certain time-points.These patients and controls would also be given on the same day as CANTAB testing, a set of questionnaires to evaluate subjective factors such as anxiety, depression, fatigue or menopausal symptoms which may also have an effect on cognition. Subjective assessment of cognitive function will rely on self-reporting by study participants using a validated questionnaire.The potential risks to subjects are minimal, as this is a study without any intervention regarding the medical management of patients. By participating in this study, subjects will be helping in the aim of determining if there is cognitive impairment post-therapy, and if so, how prevalent is this phenomenon, when it arises and how it changes with time. This will consequentially play an important role with regard to patient knowledge. Furthermore, if chemotherapy is shown to be associated with cognitive impairment, further studies can be carried out to determine the exact pathophysiology behind this phenomenon. This will allow for sensitive and timely detection of cognitive dysfunction in patients who have received chemotherapy and/or anti-hormonal therapy, and subsequently open the avenue for research in preventing or alleviating this phenomenon. This is crucial in improving patients' quality of life, social and occupational performance.
The investigators hypothesis is that systemic adjuvant therapy in the form of chemotherapy and/or anti-hormonal therapy given to primary breast cancer patients can cause cognitive impairment.
| Condition |
|---|
|
Breast Cancer |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
- Examine the variation of cognitive function at various time-points in stage I-III breast cancer patients who have undergone or are undergoing adjuvant systemic therapyTo examine the variation of cognitive function at various time-points in stage I-III breast cancer patients who have undergone or are undergoing adjuvant systemic therapy (chemotherapy and/or anti-hormonal therapy) and compare this to a group of healthy controls to evaluate if there is a difference.
- Determine which cognitive domains in particular are affected
- Assess certain other measures such as anxiety, depression, fatigue or menopausal symptoms which may have an impact on cognitive function using a set of validated questionnaires
- Compare self-perceived cognitive deficits with objective measurements
- Evaluate underlying biological pathways and susceptibility to cognitive dysfunction through blood biomarker studies, genetic polymorphisms and other mechanisms which we deem to be relevant
| Estimated Enrollment: | 100 |
| Study Start Date: | June 2012 |
| Estimated Primary Completion Date: | May 2014 (Final data collection date for primary outcome measure) |
Eligibility| Ages Eligible for Study: | 21 Years to 64 Years |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Probability Sample |
Patients being treated with breast cancer at National University Hospital (Singapore)and healthy women would be used consisting of a friend or relative of the patient.
Inclusion Criteria:
- Histologically confirmed stage I-III breast carcinoma
- < 65 years old
- Female
Exclusion Criteria:
- Previous exposure to chemotherapy/anti-hormonal therapy for any other malignancy
- Previous neoadjuvant therapy for breast cancer
- Concomitant second primary in-situ or invasive carcinoma or previous history of carcinoma/carcinoma-in-situ
- Known disease or injury to the central nervous system (including neurodegenerative diseases, epilepsy), severe visual or auditory disorders
- Motor weakness due to any cause which makes using a touchscreen computer difficult
- Known background of depression, anxiety disorders or other neurobehavioural conditions
- Ongoing use of tranquilisers or anti-depressants
- Previous neuropsychological testing
- Current or previous history of alcohol or drug dependent
Contacts and Locations| Contact: Sing Huang Tan, MBBS | +65 6779 5555 | Sing_Huang_Tan@nuhs.edu.sg |
| Singapore | |
| Nationa University Hospital | Not yet recruiting |
| Singapore, Singapore | |
| Contact: Sing Huang Tan, MBBS +65 6779 5555 Sing_Huang_Tan@nuhs.edu.sg | |
| Principal Investigator: Sing Huang Tan, MBBS | |
More Information
Publications:
| Responsible Party: | National University Hospital, Singapore |
| ClinicalTrials.gov Identifier: | NCT01596439 History of Changes |
| Other Study ID Numbers: | Version 01 |
| Study First Received: | April 2, 2012 |
| Last Updated: | May 10, 2012 |
| Health Authority: | Singapore: Domain Specific Review Boards |
Keywords provided by National University Hospital, Singapore:
|
Healthy women consisting of a friend or relative of the patient |
Additional relevant MeSH terms:
|
Breast Neoplasms Neoplasms by Site Neoplasms Breast Diseases Skin Diseases |
ClinicalTrials.gov processed this record on June 17, 2013